- Conditions
- Breast Cancer
- Interventions
- trastuzumab, paclitaxel
- Biological · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,235
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Male Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Interventions
- vorinostat, paclitaxel, bevacizumab
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Breast Cancer
- Interventions
- filgrastim, carboplatin, cyclophosphamide, melphalan, paclitaxel, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2003
- U.S. locations
- 14
- States / cities
- La Jolla, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more
- Conditions
- Breast Cancer
- Interventions
- Filgrastim (G-CSF), Carmustine, Cisplatin, Cyclophosphamide (CTX), Etoposide, Thiotepa, Peripheral Blood Stem Cell Transplantation
- Biological · Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2006
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cancer
- Interventions
- itraconazole, voriconazole
- Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 12 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- HER2 Negative Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer
- Interventions
- CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Laboratory Biomarker Analysis
- Biological · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Recurrent Breast Cancer, Metastatic Breast Cancer
- Interventions
- Ruxolitinib, Paclitaxel
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Recurrent or Metastatic Breast Cancer
- Interventions
- DHP107, IV Paclitaxel
- Drug
- Lead sponsor
- Daehwa Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Francisco, California • Boca Raton, Florida + 8 more
- Conditions
- Breast Cancer
- Interventions
- cetuximab, carboplatin
- Biological · Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 9 more
- Conditions
- Breast Cancer
- Interventions
- Ice-Sense3TM/ ProSenseTM
- Device
- Lead sponsor
- IceCure Medical Ltd.
- Industry
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 19
- States / cities
- Glendale, Arizona • Santa Ana, California • Trumbull, Connecticut + 13 more
- Conditions
- Breast Adenocarcinoma, HER2/Neu Negative, Invasive Breast Carcinoma, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Eribulin Mesylate, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment
- Drug · Other
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 39
- States / cities
- Scottsdale, Arizona • Newark, Delaware • Washington D.C., District of Columbia + 33 more
- Conditions
- Breast Cancer
- Interventions
- Fludarabine, Melphalan, Stem Cell Infusion
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Intraocular Melanoma, Melanoma (Skin)
- Interventions
- MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, ipilimumab, tyrosinase peptide, adjuvant therapy
- Biological · Procedure
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- Not listed
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Breast Cancer
- Interventions
- irofulven
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage, Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia, Aggressive NK-cell Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase Chronic Myelogenous Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Intraocular Lymphoma, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Myeloid/NK-cell Acute Leukemia, Noncutaneous Extranodal Lymphoma, Post-transplant Lymphoproliferative Disorder, Primary Central Nervous System Hodgkin Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Progressive Hairy Cell Leukemia, Initial Treatment, Prolymphocytic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
- Interventions
- Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 19 more
- Conditions
- Melanoma (Skin)
- Interventions
- MKC1106-MT
- Biological
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 5
- States / cities
- Tucson, Arizona • Los Angeles, California • Boston, Massachusetts + 2 more
- Conditions
- Breast Cancer
- Interventions
- intracavitary balloon brachytherapy, intraoperative radiation therapy
- Radiation
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 3
- States / cities
- Cleveland, Ohio
- Conditions
- Adult Solid Tumor
- Interventions
- CANscript
- Diagnostic Test
- Lead sponsor
- Mitra RxDx, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Timeline
- 2017 – 2019
- U.S. locations
- 30
- States / cities
- Gilbert, Arizona • Aurora, Colorado • Norwich, Connecticut + 23 more
- Conditions
- Recurrent Melanoma, Stage IV Melanoma
- Interventions
- bortezomib, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
- Interventions
- CI-1040
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
- Interventions
- venipuncture, radiation therapy
- Procedure · Radiation
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 3
- States / cities
- Nashville, Tennessee
- Conditions
- Melanoma (Skin)
- Interventions
- semaxanib, thalidomide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Breast Cancer
- Interventions
- Gemcitabine, Paclitaxel protein-bound particles for injectable suspension (albumin-bound)
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 201
- States / cities
- Mobile, Alabama • Scottsdale, Arizona • Aurora, Colorado + 129 more
- Conditions
- Intraocular Melanoma, Melanoma (Skin)
- Interventions
- lomustine, temozolomide, thalidomide
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- New York, New York